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Our research covers the comprehensive understanding of the physiological roles of biocatalysts (enzymes), as well as 
the reaction mechanism, the structure and properties of each enzyme. 1) Design and synthesis of transition-state 
 analogue and mechanism-based inhibitors of γ-glutamylcysteine synthetase and γ-glutamyl transpeptidase, the key 
 enzymes in glutathione biosynthesis and its metabolism, respectively. 2) Development of novel asparagine synthetase 
inhibitors and their application in cancer chemotherapy. 3) Development of intermediate analogue inhibitors of acyl-
activating enzyme superfamily that plays pivotal roles in plant hormone homeostasis and secondary metabolite bio-
synthesis of plants.
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Design and Synthesis of γ-Glutamyl
Tranpeptidase Inhibitors
Glutathione (γ-Glu-Cys-Gly) plays a central role in 
detoxifi cation of xenobiotics, and γ-glutamyl tranpeptidase 
(GGT) is a key enzyme in the metabolism of glutathione. 
We designed and synthesized transition-state analogue 
inhibitors highly mimicking glutathione to reveal the 
substrate-recognition mechanism of GGT. Structure-activity 
relationships disclosed that human GGT recognizes the 
stereochemistry of the Cys moiety and the phosphorous 
atom, and the negative charge at the Gly residue of the 
inhibitors. On the other hand, E. coli GGT showed low 
specifi city particularly with respect to the recognition of 
the negative charge at the terminal Gly, and the result 
implied that the primary substrate of E. coli GGT is not 
glutathione. Mass spectrometric analysis showed that
the inhibitor (R=Et) binds to the small subunit of GGT 
covalently in the manner that we anticipated. The crystal 
structure of a recombinant human GGT revealed that 
Lys562 strongly interacts with the negative charge at 
C-terminal Gly of glutathione and the inhibitors.
Inhibitors Targeting Asparagine Synthetase
Asparagine synthetase (ASNS) catalyzes the synthesis 
of Asn from Asp in an ATP-dependent manner. The inhibi-
tion of ASNS is highly important in enhancing and broad-
ening the effi cacy of asparaginase therapy of leukemia 
and cancer, and we have already developed the fi rst po-
tent in vitro ASNS inhibitor (1) that suppressed prolifera-
tion of asparaginase-resistant cancer cell line at 100-1000 
μM. In this study, we aim to increase in vivo activity of 
the original inhibitor by decreasing net negative charge, 
and synthesized sulfoximino-sulfamide and -sulfamate 
based inhibitors (2 and 3) using rhodium catalyzed cou-
pling of sulfoxide and sulfamide as a key step. Steady-
state kinetic characterization of these compounds, howev-
er, has revealed the necessity of a localized negative
charge on 1 that mimics that of the phosphate group in a
key acyl-adenylate reaction intermediate.
Design of Specifi c Inhibitors of Acyl-activating
Enzymes
Acyl-activating enzymes constitute a large enzyme
 superfamily that contains a number of such important 
 enzymes as for fatty acid β-oxidation and biosynthesis of 
plant secondary metabolites. In light of their common
mechanistic features involving acyl-adenylate intermedi-
ate, we designed and synthesized N-acyl adenosyl sulfa-
mide inhibitors to reveal the function of 4-coumaric acid:
CoA ligase (4CL), a key enzyme in phenylpropanoid 
biosynthesis. The synthetic compounds inhibited 4CL in
vitro, and the substituents on benzene ring signifi cantly
affected their potency. Administration of the inhibitors to
Arabidopsis caused decrease of the phenylpropanoid 
 contents. This result implied that the inhibitors were up-
taken by plant and inhibited 4CL in vivo.
Figure 1. The structure of transition-state analogue inhibitors and sub-
strate binding pocket of human GGT.
Figure 2. (Left) The structure of the original inhibitor (1) and newly
synthesized inhibitors (2 and 3). (Right) X-Ray crystal structure of E.
coli ASNS in complex with 1.
Figure 3. The outline of phenylpropanoid biosynthesis and the structure
of intermediate analogue inhibitors.
